AUSTIN – A team of Pillsbury lawyers led clinical-stage pharmaceutical company, Plus Therapeutics (Nasdaq: PSTV), on an in-licensing transaction in exchange for stock, cash, milestones and royalties.

Austin-based Plus Therapeutics announced the closing of its previously announced definitive agreement to license multiple rare cancer product candidates from private Texas-based radiotherapeutic company NanoTx Therapeutics.

The Pillsbury team was led by Houston-based Corporate partner Andrew Strong and included special counsel Barry Burgdorf, associates Daniel Garcia and Nick Griffin, and San Diego-based Intellectual Property counsel Michelle Mehok.